Innate Pharma (IPHYF) Upgraded at Zacks Investment Research

Zacks Investment Research upgraded shares of Innate Pharma (NASDAQ:IPHYF) from a sell rating to a hold rating in a research report report published on Wednesday.

According to Zacks, “Innate Pharma S.A. is a biopharmaceutical company. It develops drugs for treatment of cancer and inflammatory diseases. The company specializes in the development of first-in-class therapeutic antibodies targeting receptors and pathways controlling the activation of the innate immune system. Innate Pharma S.A. is headquartered in Marseilles, France. “

Separately, HC Wainwright assumed coverage on shares of Innate Pharma in a research report on Wednesday, August 30th. They set a buy rating on the stock.

Shares of Innate Pharma (IPHYF) opened at $10.80 on Wednesday.

WARNING: This story was first reported by Community Financial News and is the sole property of of Community Financial News. If you are reading this story on another domain, it was stolen and reposted in violation of United States & international copyright law. The original version of this story can be accessed at https://www.com-unik.info/2017/11/04/innate-pharma-iphyf-upgraded-at-zacks-investment-research.html.

Get a free copy of the Zacks research report on Innate Pharma (IPHYF)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

What are top analysts saying about Innate Pharma? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Innate Pharma and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit